Respiratory syncytial virus (RSV) is the most common cause of respiratory infection in infants and the elderly, and no vaccine against this virus has yet been licensed. In this report, a recombinant PR8 influenza virus with the RSV fusion protein epitopes of the subgroup A gene inserted into the influenza virus nonstructural (NS) gene (rFlu/RSV/F) was generated as an RSV vaccine candidate. The rescued viruses were assessed by microscopy and Western blotting. The proper expression of NS1, the NS gene product, and the nuclear export protein (NEP) of rFlu/RSV/F were also investigated using an immunofluorescent assay. The rescued virus replicated well in the MDCK kidney cell line, A549 lung adenocarcinoma cell line, and the CNE-2Z nasopharyngeal carcinoma cell line. BALB/c mice immunized intranasally with rFlu/RSV/F had specific hemagglutination inhibition antibody responses against the PR8 influenza virus and RSV NT proteins. Furthermore, intranasal immunization with rFlu/RSV/F elicited Th1-dominant cytokine profiles against the RSV-A2 virus. Taken together, our findings suggest that rFlu/RSV/F is immunogenic in vivo, and warrants further development as a promising candidate vaccine.